Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Operating Expenses (2016 - 2023)

Historic Operating Expenses for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $4.8 million.

  • RedHill Biopharma's Operating Expenses fell 4819.75% to $4.8 million in Q2 2023 from the same period last year, while for Dec 2024 it was $4.8 million, marking a year-over-year decrease of 7520.6%. This contributed to the annual value of $11.7 million for FY2024, which is 4458.76% down from last year.
  • RedHill Biopharma's Operating Expenses amounted to $4.8 million in Q2 2023, which was down 4819.75% from $6.9 million recorded in Q1 2023.
  • Over the past 5 years, RedHill Biopharma's Operating Expenses peaked at $20.6 million during Q2 2021, and registered a low of $4.8 million during Q2 2023.
  • Its 5-year average for Operating Expenses is $10.0 million, with a median of $9.2 million in 2020.
  • In the last 5 years, RedHill Biopharma's Operating Expenses surged by 12237.48% in 2021 and then crashed by 5507.95% in 2022.
  • Over the past 5 years, RedHill Biopharma's Operating Expenses (Quarter) stood at $6.4 million in 2019, then skyrocketed by 112.48% to $13.6 million in 2020, then fell by 8.43% to $12.5 million in 2021, then tumbled by 38.78% to $7.6 million in 2022, then tumbled by 37.31% to $4.8 million in 2023.
  • Its Operating Expenses stands at $4.8 million for Q2 2023, versus $6.9 million for Q1 2023 and $7.6 million for Q4 2022.